Indian Pharma Market growth stable in August 2021
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Terumo’s first product was the domestically produced, safe, high-quality thermometer. The company has since supported the healthcare ecosystem worldwide
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated